935 related articles for article (PubMed ID: 18700841)
1. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
2. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
3. Assessment of haemophilia treatment practice pattern in Japan.
Ono O; Suzuki Y; Yosikawa K; Wada I; Doi Y; Takano M; Wada Y; Fukushima K;
Haemophilia; 2009 Sep; 15(5):1032-8. PubMed ID: 19476508
[TBL] [Abstract][Full Text] [Related]
4. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis therapy in haemophilia A: current situation in Spain.
Lucía JF; Aznar JA; Abad-Franch L; Escuin RR; Jiménez-Yuste V; Pérez R; Batlle J; Balda I; Alperovich G; Parra R;
Haemophilia; 2011 Jan; 17(1):75-80. PubMed ID: 21070481
[TBL] [Abstract][Full Text] [Related]
6. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
7. [Haemophilia A, B or von Willebrand disease type 3. Census of patients in the eastern part of Germany].
Scholz U; Syrbe G; Koscielny J; Klamroth R;
Hamostaseologie; 2008; 28(3):150-4. PubMed ID: 18521493
[TBL] [Abstract][Full Text] [Related]
8. Practice patterns in haemophilia A therapy -- global progress towards optimal care.
Geraghty S; Dunkley T; Harrington C; Lindvall K; Maahs J; Sek J
Haemophilia; 2006 Jan; 12(1):75-81. PubMed ID: 16409179
[TBL] [Abstract][Full Text] [Related]
9. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
[TBL] [Abstract][Full Text] [Related]
10. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
11. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
12. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy.
Castaman G; Rocino A; Mazzucconi MG; Zanon E; Gagliano F; Molinari AC
Blood Transfus; 2015 Oct; 13(4):631-8. PubMed ID: 26057481
[TBL] [Abstract][Full Text] [Related]
14. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
[TBL] [Abstract][Full Text] [Related]
15. Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
Khawaji M; Akesson K; Berntorp E
Haemophilia; 2009 Jan; 15(1):261-6. PubMed ID: 19149852
[TBL] [Abstract][Full Text] [Related]
16. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
17. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
18. The overall effectiveness of prophylaxis in severe haemophilia.
Panicker J; Warrier I; Thomas R; Lusher JM
Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
Walsh CE; Valentino LA
Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
